$6.11
-0.11 (-1.69%)
Open$6.24
Previous Close$6.21
Day High$6.54
Day Low$5.96
52W High$44.40
52W Low$4.07
Volume—
Avg Volume154.8K
Market Cap15.81M
P/E Ratio—
EPS$-25.14
SectorBiotechnology
Analyst Ratings
Buy
15 analysts
Price Target
+93.6% upside
Current
$6.11
$6.11
Target
$11.82
$11.82
$9.31
$11.82 avg
$19.97
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 207.3K | 786.7K | 11.28M |
| Net Income | -80,898,259 | -276,312,839 | 2.04M |
| Profit Margin | -39,009.5% | -37,059.0% | 18.1% |
| EBITDA | -84,003,387 | -302,858,511 | 2.88M |
| Free Cash Flow | — | — | 1.40M |
| Rev Growth | -73.7% | -73.7% | +22.8% |
| Debt/Equity | 0.01 | 0.01 | 0.20 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $295.03 | +0.20% | 50.3 | 520.47B |
| AMGN | Amgen Inc | $465.67 | -0.30% | 26.9 | 252.64B |
| GILD | Gilead Sciences Inc | $168.08 | +0.08% | — | 208.95B |
| VRTX | Vertex Pharmaceuticals Inc | $538.60 | -0.74% | 33.9 | 134.82B |
| REGN | Regeneron Pharmaceuticals | $955.47 | +0.45% | 20.4 | 98.38B |
| ALNY | Alnylam Pharmaceuticals Inc | $165.04 | +5.36% | 7.7 | 20.98B |